Equities

BioCardia Inc

BioCardia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.35
  • Today's Change0.023 / 6.90%
  • Shares traded216.29k
  • 1 Year change-78.66%
  • Beta1.4225
Data delayed at least 15 minutes, as of May 24 2024 17:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

  • Revenue in USD (TTM)468.00k
  • Net income in USD-10.34m
  • Incorporated1994
  • Employees16.00
  • Location
    BioCardia Inc320 Soquel WaySUNNYVALE 94085United StatesUSA
  • Phone+1 (650) 226-0123
  • Fax+1 (650) 631-3731
  • Websitehttps://www.biocardia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CV Sciences Inc15.86m-3.23m8.32m42.00--3.52--0.525-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Odonate Inc0.00-102.07m8.33m137.00--307.35-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
eFFECTOR Therapeutics Inc0.00-34.63m8.56m14.00--8.59-----13.31-13.310.000.21190.00----0.00-141.18-----------------17.120.9581---100.00---58.00------
Energy Finders Inc4.06m-2.92m8.61m46.00------2.12-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
Kintara Therapeutics Inc0.00-9.51m8.68m2.00---------4.08-4.080.000.10710.00----0.00-131.55-220.94-185.60-329.97------------0.00------40.24--78.93--
Molecular Templates Inc31.76m-18.40m8.69m62.00--1.21--0.2736-4.36-4.365.981.090.6014--19.55512,306.40-34.83-51.78-54.80-73.14-----57.92-228.33---52.110.00--190.1033.9691.24---48.87--
Protext Mobility Inc750.00-2.21m8.79m4.00------11,721.63-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
BioRestorative Therapies Inc145.80k-14.42m8.94m11.00--0.5387--61.29-3.54-3.540.03462.450.01--8.2613,254.55-99.26-199.86-104.68-334.04-----9,887.16-19,887.03----0.00--21.705.6122.06--67.77--
BioCardia Inc468.00k-10.34m8.94m16.00------19.10-0.4692-0.46920.0209-0.08480.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Endexx Corp4.64m6.93m9.11m--1.35--1.541.970.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
Ayala Pharmaceuticals Inc13.00k-48.07m9.17m20.00------705.09-7.46-7.460.0022-2.06------650.00--------0.00---369,784.60-----2.31----------------
Transcode Therapeutics Inc0.00-17.06m9.20m10.00--1.76-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Weed Inc0.00-5.19k9.21m2.00--85.66235.08---0.00001-0.000010.000.00090.00----0.00-0.4942-385.93-9.56-822.37-----------23.030.5461------97.93---59.13--
Vaxxinity Inc0.00-56.94m9.26m57.00--0.69-----0.4499-0.44990.000.10580.00----0.00-75.56---111.46--------------0.5308------24.31------
Pacific Software Inc0.00-77.46k9.36m0.00--0.3008-----0.1832-0.18320.000.76460.00-------26.19-620.48-66.38-------------6.290.00-------13.29------
BioNexus Gene Lab Corp9.78m-2.66m9.61m30.00--1.03--0.9832-0.14-0.140.6510.52891.018.555.80---27.53-3.83-33.16-5.0213.5614.55-27.25-3.043.98-162.450.00---10.60115.07-638.56--30.40--
Data as of May 24 2024. Currency figures normalised to BioCardia Inc's reporting currency: US Dollar USD

Institutional shareholders

6.92%Per cent of shares held by top holders
HolderShares% Held
CM Management LLCas of 31 Mar 2024700.00k2.61%
The Vanguard Group, Inc.as of 31 Mar 2024646.74k2.41%
Geode Capital Management LLCas of 31 Mar 2024155.86k0.58%
Two Sigma Securities LLCas of 31 Mar 2024111.08k0.41%
Family Management Corp.as of 31 Mar 202477.50k0.29%
BlackRock Fund Advisorsas of 31 Mar 202441.84k0.16%
Virtu Americas LLCas of 31 Dec 202341.35k0.15%
Brown Advisory LLCas of 31 Mar 202433.09k0.12%
Commonwealth Equity Services LLCas of 31 Mar 202430.00k0.11%
Securities America Advisors, Inc.as of 31 Mar 202421.37k0.08%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.